How to buy Trevena stock | $1.11

Trevena Inc is a biotechnology business based in the US. Trevena shares (TRVN) are listed on the NASDAQ and all prices are listed in US Dollars. Trevena employs 25 staff and has a trailing 12-month revenue of around 0.00.

Trevena stock price (NASDAQ: TRVN)

Use our graph to track the performance of TRVN stocks over time.

Trevena shares at a glance

• Key figures

Information last updated 2021-10-16.

Latest market close	$1.11
52-week range	$1.09 - $3.10
50-day moving average	$1.24
200-day moving average	$1.55
Wall St. target price	$5.33
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.26

Buy Trevena shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Trevena stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Trevena price performance over time

Historical closes compared with the close of $1.11 from 2021-10-19

1 week (2021-10-14)	-4.31%
1 month (2021-09-21)	-9.02%
3 months (2021-07-21)	-30.63%
6 months (2021-04-21)	-36.57%

1 year (2020-10-20)	-60.07%
2 years (2019-10-18)	19.35%
3 years (2018-10-19)	34.77%
5 years (2016-10-20)	5.9

Trevena financials

Revenue TTM	$3.5 million
Gross profit TTM	$2.9 million
Return on assets TTM	-29.1%
Return on equity TTM	-56.62%
Profit margin	0%
Book value	$0.55
Market capitalisation	$187.5 million

TTM: trailing 12 months

Shorting Trevena shares

There are currently 14.2 million Trevena shares held short by investors – that's known as Trevena's "short interest". This figure is 3.4% down from 14.7 million last month.

There are a few different ways that this level of interest in shorting Trevena shares can be evaluated.

Trevena's "short interest ratio" (SIR)

Trevena's "short interest ratio" (SIR) is the quantity of Trevena shares currently shorted divided by the average quantity of Trevena shares traded daily (recently around 918619.93527508). Trevena's SIR currently stands at 15.45. In other words for every 100,000 Trevena shares traded daily on the market, roughly 15450 shares are currently held short.

However Trevena's short interest can also be evaluated against the total number of Trevena shares, or, against the total number of tradable Trevena shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Trevena's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Trevena shares in existence, roughly 90 shares are currently held short) or 0.0871% of the tradable shares (for every 100,000 tradable Trevena shares, roughly 87 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Trevena.

Find out more about how you can short Trevena stock.

Trevena share dividends

We're not expecting Trevena to pay a dividend over the next 12 months.

Trevena share price volatility

Over the last 12 months, Trevena's shares have ranged in value from as little as $1.091 up to $3.1. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Trevena's is 2.4058. This would suggest that Trevena's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Trevena overview

Trevena, Inc. , a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist that has completed Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania. .

Frequently asked questions

What percentage of Trevena is owned by insiders or institutions?
Currently 0.656% of Trevena shares are held by insiders and 21.865% by institutions. How many people work for Trevena?
Latest data suggests 25 work at Trevena. When does the fiscal year end for Trevena?
Trevena's fiscal year ends in December. Where is Trevena based?
Trevena's address is: 955 Chesterbrook Boulevard, Chesterbrook, PA, United States, 19087 What is Trevena's ISIN number?
Trevena's international securities identification number is: US89532E1091 What is Trevena's CUSIP number?
Trevena's Committee on Uniform Securities Identification Procedures number is: 89532E109